标题
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma
作者
关键词
-
出版物
ACTA ONCOLOGICA
Volume 53, Issue 10, Pages 1436-1440
出版商
Informa UK Limited
发表日期
2014-05-26
DOI
10.3109/0284186x.2014.920960
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma
- (2014) Benedikt Wiestler et al. JOURNAL OF NEURO-ONCOLOGY
- Tumor-associated edema in brain cancer patients: pathogenesis and management
- (2013) Patrick Roth et al. Expert Review of Anticancer Therapy
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- Standards of care for treatment of recurrent glioblastoma—are we there yet?
- (2012) Michael Weller et al. NEURO-ONCOLOGY
- Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
- (2011) David A. Reardon et al. CANCER
- Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- The paradoxical effect of bevacizumab in the therapy of malignant gliomas
- (2010) E. M. Thompson et al. NEUROLOGY
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
- (2009) Joost JC Verhoeff et al. BMC CANCER
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
- (2008) A. Claes et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started